Despite the significant successes of these treatments, resistance in CML patients has been observed, particularly in those with a mutation leading to the substitution of threonine with isoleucine at position 315 (T315I) in the BCR–ABL1 kinase domain. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.